Sotatercept/luspatercept trials for β-thalassemia
| Trial identifier . | Phase/status . | Enrolled patients . | Drug product . | Sponsor/center . |
|---|---|---|---|---|
| NCT01571635 | Phase 2; active, not recruiting | 16 TDT, 30 NTDT | Sotatercept (ACE-011) | Celgene; multicenter international sites |
| NCT01749540 | Phase 2; completed | 31 TDT, 33 NTDT | Luspatercept (ACE-536) | Acceleron Pharma; multicenter international sites |
| NCT02604433 | Phase 3; completed, not recruiting | 336 TDT | Luspatercept (ACE-536) | Celgene and Acceleron Pharma; ulticenter international sites |
| NCT03342404 | Phase 2; ongoing, not recruiting | 145 NTDT | Luspatercept (ACE-536) | Celgene and Acceleron Pharma; multicenter international sites |
| Trial identifier . | Phase/status . | Enrolled patients . | Drug product . | Sponsor/center . |
|---|---|---|---|---|
| NCT01571635 | Phase 2; active, not recruiting | 16 TDT, 30 NTDT | Sotatercept (ACE-011) | Celgene; multicenter international sites |
| NCT01749540 | Phase 2; completed | 31 TDT, 33 NTDT | Luspatercept (ACE-536) | Acceleron Pharma; multicenter international sites |
| NCT02604433 | Phase 3; completed, not recruiting | 336 TDT | Luspatercept (ACE-536) | Celgene and Acceleron Pharma; ulticenter international sites |
| NCT03342404 | Phase 2; ongoing, not recruiting | 145 NTDT | Luspatercept (ACE-536) | Celgene and Acceleron Pharma; multicenter international sites |
From www.clinicaltrials.gov. In all studies, the route of administration was subcutaneous, and the target was ineffective erythropoiesis.